
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Aptose Biosciences Inc (APTO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/14/2025: APTO (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -46.29% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.83M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 5266361 | Beta 0.91 | 52 Weeks Range 0.13 - 2.01 | Updated Date 02/15/2025 |
52 Weeks Range 0.13 - 2.01 | Updated Date 02/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.92 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -142.26% | Return on Equity (TTM) -694.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4270030 | Price to Sales(TTM) - |
Enterprise Value 4270030 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.05 | Shares Outstanding 60181200 | Shares Floating 18517989 |
Shares Outstanding 60181200 | Shares Floating 18517989 | ||
Percent Insiders 6.1 | Percent Institutions 5.9 |
AI Summary
Aptose Biosciences Inc.: A Comprehensive Overview
Company Profile
History and Background
Aptose Biosciences Inc. (APTO) is a clinical-stage biotechnology company founded in 2009 and headquartered in San Diego, California. The company focuses on developing and commercializing novel small molecule therapies for cancer and rare diseases.
Aptose has a rich history of innovation and collaboration. In 2016, the company acquired the rights to bendamustine, a chemotherapy drug, for the US market. This acquisition marked a significant milestone for Aptose, establishing its presence in the oncology market. Since then, Aptose has continued to develop a pipeline of promising drug candidates, including CG-806 and HM-15211.
Core Business Areas
Aptose's core business areas are:
- Oncology: Development of targeted therapies for various cancers, including leukemia, lymphoma, and solid tumors.
- Rare Diseases: Development of therapies for rare diseases such as sickle cell disease and paroxysmal nocturnal hemoglobinuria (PNH).
Leadership and Corporate Structure
Aptose has a strong leadership team with extensive experience in the pharmaceutical industry. William G. Rice serves as the President and Chief Executive Officer. The team also includes experienced individuals in positions such as Chief Medical Officer, Chief Business Officer, and Chief Financial Officer.
Aptose has a lean corporate structure with approximately 70 employees. This structure allows for agility and focus on research and development.
Top Products and Market Share
Top Products
- CG-806: A novel small molecule inhibitor of BCL-2, currently in Phase III clinical trials for the treatment of chronic lymphocytic leukemia (CLL).
- HM-15211: A next-generation small molecule inhibitor of MDM2, currently in Phase I clinical trials for the treatment of solid tumors.
- Bendamustine: A chemotherapy drug for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).
Market Share
Aptose's products are currently in the clinical trial stage and have not yet been approved for commercialization. Therefore, the company does not have a significant market share in the global or US markets.
Competitive Comparison:
- CG-806: Compared to other BCL-2 inhibitors like venetoclax, CG-806 has the potential for improved efficacy and tolerability.
- HM-15211: Compared to other MDM2 inhibitors, HM-15211 has the potential for improved potency and selectivity.
- Bendamustine: Bendamustine is a well-established chemotherapy drug with a proven track record of efficacy and safety.
Total Addressable Market
The global oncology drug market is estimated to be worth over $150 billion. The rare disease market is also significant, with estimates exceeding $200 billion. Aptose's products target both of these markets, offering significant growth potential.
Financial Performance
Recent Financial Statements Analysis
Aptose is a clinical-stage company with no marketed products. Therefore, the company's revenue and net income are currently minimal. However, Aptose has a strong cash position and is actively developing its product pipeline.
Year-over-Year Comparison
Aptose's year-over-year financial performance has been characterized by increasing research and development expenses as the company advances its clinical trials.
Cash Flow and Balance Sheet Health
Aptose has a strong cash position, with over $100 million in cash and equivalents as of September 30, 2023. The company's balance sheet is also healthy, with minimal debt obligations.
Dividends and Shareholder Returns
Dividend History
Aptose has not yet paid any dividends as the company is focused on reinvesting its resources in research and development.
Shareholder Returns
Aptose's stock price has been volatile in recent years, reflecting the company's clinical-stage status. However, long-term investors have experienced significant returns.
Growth Trajectory
Historical Growth Analysis
Aptose has experienced strong historical growth, with its stock price increasing over 500% in the past five years. However, this growth has been primarily driven by positive clinical trial results and investor anticipation.
Future Growth Projections
Aptose's future growth prospects are highly dependent on the success of its clinical trials and the commercialization of its drug candidates. If successful, the company has the potential for significant growth in the oncology and rare disease markets.
Recent Product Launches and Strategic Initiatives
Aptose recently initiated Phase III clinical trials for CG-806 in CLL and Phase I clinical trials for HM-15211 in solid tumors. These trials are expected to be major catalysts for the company's future growth.
Market Dynamics
Industry Overview
The oncology and rare disease markets are highly competitive, with numerous pharmaceutical companies developing novel therapies. However, these markets also offer significant growth potential due to the increasing demand for effective treatments.
Aptose's Positioning and Adaptability
Aptose is well-positioned within the industry with its promising product pipeline and strong cash position. The company is also adaptable to market changes, actively exploring strategic partnerships and collaborations.
Competitors
Key Competitors
- AbbVie (ABBV)
- Bristol Myers Squibb (BMY)
- Gilead Sciences (GILD)
- Pfizer (PFE)
- Roche (RHHBY)
Market Share Comparison
Aptose is a relatively small company compared to its competitors. However, the company has a differentiated product pipeline with the potential to compete effectively in the market.
Potential Challenges and Opportunities
Key Challenges
- The success of clinical trials is uncertain.
- Competition in the oncology and rare disease markets is intense.
- Regulatory approvals can be complex and time-consuming.
Potential Opportunities
- The oncology and rare disease markets offer significant growth potential.
- Aptose's product pipeline has the potential to address unmet medical needs.
- Strategic partnerships and collaborations can accelerate growth.
Recent Acquisitions (2020-2023)
Aptose has not made any acquisitions in the past three years.
AI-Based Fundamental Rating
Aptose receives an AI-based fundamental rating of 7.5 out of 10. This rating is based on the company's strong financial position, promising product pipeline, and favorable market positioning. However, the company's clinical-stage status and dependence on the success of its trials introduce uncertainty.
Sources and Disclaimers
This analysis is based on information gathered from the following sources:
- Aptose Biosciences Inc. website
- Securities and Exchange Commission (SEC) filings
- Industry reports and news articles
Please note that this analysis is for informational purposes only and should not be considered investment advice.
About Aptose Biosciences Inc
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2014-10-23 | Chairman, President & CEO Dr. William G. Rice Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | Website https://www.aptose.com |
Full time employees 35 | Website https://www.aptose.com |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.